A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

By afschroeder • August 15, 2025

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer. Lung Cancer. 2025 Aug 6;207:108701. doi: 10.1016/j.lungcan.2025.108701. Epub ahead of print. PMID: 40811940.

Tags: Alectinib, anaplastic lymphoma kinase, chemotherapy, Costs and Cost Analysis, Hematology/Oncology, Non-small cell lung cancer, Publications, Pulmonary, Critical Care & Sleep Medicine, Statistical model, Tyrosine kinase inhibitors

Related Posts

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchán J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies

Shan NL, Balinda H, Dai J, Wang Y, Lin HK, Marczyk M, Espinoza Campos G, Umlauf S, McDermott MSJ, Colorado I, Lang SM, Surovtseva YV,[...]

Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu[...]